Notably, mice treated with anti–TIM-3 Ab without allogeneic Tc transfer were not protected from FLT3-ITD MLL-PTD–driven AML (Figure 1J), indicating that anti–TIM-3 Ab requires allo-HCT to exert its effects. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.